Surface modification of silicone breast implants by binding the antifibrotic drug halofuginone reduces capsular fibrosis

Plastic and Reconstructive Surgery

Volumn 126, Issue 1, 2010, Pages 266-274

  Zeplin, Philip H ^a   Larena Avellaneda, Axel ^a   Schmidt, Karsten ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; COLLAGEN TYPE 1; HALOFUGINONE; PIPERIDINE DERIVATIVE; PROTEIN SYNTHESIS INHIBITOR; QUINAZOLINONE DERIVATIVE; SILICON;

ANIMAL; ARTICLE; BIOSYNTHESIS; BREAST ENDOPROSTHESIS; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; FEMALE; FIBROSIS; FOREIGN BODY REACTION; METABOLISM; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME; UDDER;

ANIMALS; BREAST IMPLANTS; COATED MATERIALS, BIOCOMPATIBLE; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; FOREIGN-BODY REACTION; MAMMARY GLANDS, ANIMAL; PIPERIDINES; PROTEIN SYNTHESIS INHIBITORS; QUINAZOLINONES; RATS; RATS, SPRAGUE-DAWLEY; SILICON; TREATMENT OUTCOME;

EID: 77954632753     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e3181dbc313     Document Type: Article

References (45)

1. Alfano C, Mazzocchi M, Scuderi N. Mammary compliance: An objective measurement of capsular contracture. Aesthetic Plast Surg. 2004;28:75-79.
2. Henriksen TF, Hölmich LR, Fryzek JP, et al. Incidence and severity of short-term complications after breast augmentation: Results from a nationwide breast implant registry. Ann Plast Surg. 2003;51:531-539.
3. McGrath MH, Burkhardt BR. The safety and efficacy of breast implants for augmentation mammaplasty. Plast Reconstr Surg. 1984;74:550-560.
4. Handel N, Cordray T, Gutierrez J, Jensen JA. A long-term study of outcomes, complications, and patient satisfaction with breast implants. Plast Reconstr Surg. 2006;117:757-767.
5. Embrey M, Adams EE, Cunningham B, Peters W, Young VL, Carlo GL. A review of the literature on the etiology of capsular contracture and a pilot study to determine the outcome of capsular contracture interventions. Aesthetic Plast Surg. 1999;23:197-206.
6. Hipps CJ, Raju R, Straith RE. Influence of some operative and postoperative factors on capsular contracture around breast prostheses. Plast Reconstr Surg. 1978;61:384-389.
7. Iwuagwu FC, Frame JD. Silicone breast implants: Complications. Br J Plast Surg. 1997;50:6632-6636.
8. Stock W, Wolf K. Capsule fibrosis in silicone implants. Langenbecks Arch Chir. 1986;369:303-308.
9. Schreml S, Heine N, Eisenmann-Klein M, Prantl L. Bacterial colonization is of major relevance for high-grade capsular contracture after augmentation mammaplasty. Ann Plast Surg. 2007;59:126-130.
10. Adams Jr. WP. Capsular contracture: What is it? What causes it? How can it be prevented and managed? Clin Plast Surg. 2009;36:119-126.
11. Dobke MK, Svahn JK, Vastine VL, Landon BN, Stein PC, Parsons CL. Characterization of microbial presence at the surface of silicone mammary implants. Ann Plast Surg. 1995; 34:563-571.
12. Barnsley GP, Sigurdson LJ, Barnsley SE. Textured surface breast implants in the prevention of capsular contracture among breast augmentation patients: A meta-analysis of randomized controlled trials. Plast Reconstr Surg. 2006;117:2182-2190.
13. Brohim RM, Foresman PA, Hildebrandt PK, Rodeheaver GT. Early tissue reaction to textured breast implant surfaces. Ann Plast Surg. 1992;28:354-362.
14. Carpaneda CA. Inflammatory reaction and capsular contracture around smooth silicone implants. Aesthetic Plast Surg. 1997;21:110-114.
15. Wong CH, Samuel M, Tan BK, Song C. Capsular contracture in subglandular breast augmentation with textured versus smooth breast implants: A systematic review. Plast Reconstr Surg. 2006;118:1224-1236.
16. Cafee HH. The influence of silicone bleed on capsular contracture. Ann Plast Surg. 1986;17:284-287.
17. Chang L, Caldwell E, Reading G, Wray Jr. RC. A comparison of conventional and low-bleed implants in augmentation mammaplasty. Plast Reconstr Surg. 1992;89:79-82.
18. Gancedo M, Ruiz-Corro L, Salazar-Montes A, Rincón AR, Armendáriz-Borunda J. Pirfenidone prevents capsular contracture after mammary implantation. Aesthetic Plast Surg. 2008;32:32-40.
19. Ruiz-de-Erenchun R, Dotor De Las Herrerías J, Hontanilla B. Use of the transforming growth factor-beta1 inhibitor peptide in periprosthetic capsular fibrosis: Experimental model with tetraglycerol dipalmitate. Plast Reconstr Surg. 2005;116: 1370-1378.
20. Spano A, Palmieri B, Taidelli TP, Nava MB. Reduction of capsular thickness around silicone breast implants by zafirlukast in rats. Eur Surg Res. 2008;41:8-14.
21. Jagadeesan J, Bayat A. Transforming growth factor beta (TGFbeta) and keloid disease. Int J Surg. 2007;5:278-285.
22. Gnainsky Y, Kushnirsky Z, Bilu G, et al. Gene expression during chemically induced liver fibrosis: Effect of halofuginone on TGF-beta signaling. Cell Tissue Res. 2007; 328:153-166.
23. Bruck R, Genina O, Aeed H, et al. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 2001;33:379-386.
24. Bhattacharyya S, Chen SJ, Wu M, et al. Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: Implications for scleroderma. Am J Pathol. 2008;173:1085-1099.
25. Chen SJ, Yuan W, Mori Y, Levenson A, Trojanowska M, Varga J. Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: Involvement of Smad 3. J Invest Dermatol. 1999;112:49-57.
26. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol. 2004;85:47-64.
27. Pines M, Nagler A. Halofuginone: A novel antifibrotic therapy. Gen Pharmacol. 1998;30:445-450. (Pubitemid 28102819)
28. Granot I, Halevy O, Hurwitz S, Pines M. Halofuginone: An inhibitor of collagen type I synthesis. Biochim Biophys Acta 1993;1156:107-112.
29. McGaha TL, Phelps RG, Spiera H, Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor- beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol. 2002;118:461-470.
30. Leiba M, Cahalon L, Shimoni A, et al. Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells. J Leukoc Biol. 2006;80:399-406.
31. Spira G, Mawasi N, Paizi M, et al. Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats. J Hepatol. 2002;37:331-339.
32. Pines M, Domb A, Ohana M, et al. Reduction in dermal fibrosis in the tight skin (Tsk) mouse after local application of halofuginone. Biochem Pharmacol. 2001;62:1221-1227.
33. Pines M, Snyder D, Yarkoni S, Nagler A. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant. 2003;9:417-425.
34. Olbrich KC, Meade R, Bruno W, Heller L, Klitzman B, Levin LS. Halofuginone inhibits collagen deposition in fibrous capsules around implants. Ann Plast Surg. 2005;54:293-296.
35. Henriksen TF, Fryzek JP, Hölmich LR, et al. Surgical intervention and capsular contracture after breast augmentation: A prospective study of risk factors. Ann Plast Surg. 2005;54:343-351.
36. Friedmann J, Bauer M, Golz B, et al. Physiologic and pathologic patterns of reaction to silicone breast implants. Zentralbl Chir. 1997;122:551-564.
37. Wolfram D, Rainer C, Niederegger H, Piz H, Wick G. Cellular and molecular composition of fibrous capsules formed around silicone breast implants with special focus on immune reactions. J Autoimmun. 2004;23:81-91.
38. Gayou RM. A histological comparison of contracted and non-contracted capsules around silicon breast implants. Plast Reconstr Surg. 1979;63:700-707.
39. Poeppl N, Schreml S, Lichtenegger F, Lenich A, Eisenmann- Klein M, Prantl L. Does the surface structure of implants have an impact on the formation of a capsular contracture? Aesthetic Plast Surg. 2007;31:133-139.
40. Prantl L, Schreml S, Fichtner-Feigl S, et al. Histological and immunohistochemical investigations with capsular contracture after breast augmentation with smooth silicone gel implants. Handchir Mikrochir Plast Chir. 2006;38:224-232. (Pubitemid 44433763)
41. Sergott TJ, Limoli JP, Baldwin Jr. CM, Laub DR. Human adjuvant disease, possible autoimmune disease after silicone implantation: A review of the literature, case studies, and speculation for the future. Plast Reconstr Surg. 1986; 78:104-114.
42. Pajkos A, Deva AK, Vickery K, Cope C, Chang L, Cossart YE. Detection of subclinical infection in significant breast implant capsules. Plast Reconstr Surg. 2003;111:1605-1611.
43. Kuhn A, Singh S, Smith PD, et al. Periprosthetic breast capsules contain the fibrogenic cytokines TGF-beta1 and TGFbeta2, suggesting possible new treatment approaches. Ann Plast Surg. 2000;44:387-391.
44. Shah M, Foreman DM, Ferguson MW. Neutralisation of TGFbeta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci. 1995; 108:985-1002.
45. Shah M, Foreman DM, Ferguson MW. Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents. J Cell Sci. 1994;107:1137-1157.